This brand name is authorized in Japan
The drug SOMAZON contains one active pharmaceutical ingredient (API):
|
1
Mecasermin
UNII 7GR9I2683O - MECASERMIN
|
|
Mecasermin is a human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology. Insulin-like growth factor-1 (IGF-1) is the principal hormonal mediator of statural growth. Mecasermin is indicated for the long-term treatment of growth failure in patients with confirmed severe primary insulin-like growth factor-1 deficiency (Primary IGFD). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H01AC03 | Mecasermin | H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01A Anterior pituitary lobe hormones and analogues → H01AC Somatropin and somatropin agonists |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 2499408D1028 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
